Contracted drug production – stay ahead now by exploring leading companies’ prospects How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s updated report shows you their prospects to 2025. You discover that outsourcing industry’s results, trends, opportunities and potentials, also with predicted revenues and profits.
Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market’s potential, benefiting your reputation for commercial insight.
That way you find analysis on established and emerging companies across the world. Read on, please, to scan the leading companies and see revenue prediction for their industry.
Forecasts and other data to help you stay ahead, benefiting your influence In our new study you find analytical profiles of 30 top contractors, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. Also explore qualitative analyses, business outlooks and developments.
Our study gives you 185 tables, 111 charts and three interviews with companies.
That investigation also shows you prospects for these outsourced production segments at world level, including their overall revenue forecasts to 2025: • Active pharmaceutical ingredients (API) production • Finished dosage formulations (FDF) manufacturing.
In particular, biologics and biosimilars hold promise. New therapies – including antibody-drug conjugates, high potency APIs and regenerative medicines – increasingly interest CMOs and clients.
Discover, then, what the future holds. The following sections highlight what our research and analyses give you, to benefit planning, proposals and presentations.
Company profiles – explore commercial activities, results, competition and prospects Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information: • Overview of the company’s contract manufacturing services and operations • Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins • Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations • SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards • Forecasting of pharmaceutical manufacturing revenue to 2025 (for 26 firms), as well as projected operating profit and margin for some companies.
Pharmaceutical developers, producers and marketers will increasingly use CMOs. With our study you discover what that industry’s participants offer – along with their trends and revenue potentials – helping you stay ahead in knowledge and benefit your authority.
European contract manufacturing organisations Our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms: • Lonza • Evonik Degussa • Royal DSM • Boehringer Ingelheim • Fareva • Famar • Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2025. What profitability and other achievements are possible?
CMOs based in the US and Japan Our report also shows you developments and business outlooks for seven other international drug production contractors: • Catalent Pharma Solutions • Patheon • Baxter BioPharma Solutions • AbbVie Contract Manufacturing • Pfizer CentreSource • Daito Pharmaceutical • Nipro Corporation.
Our work reveals where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2015. You discover where prospects for sales expansion exist, seeing what is possible for that business and its leading competitors.
Developed-market API specialists You also discover outlooks for three top producers of active pharmaceutical ingredients: • Teva API • Esteve Química • Euticals.
Our report shows commercial potentials of that industry. You see possibilities for advancing medical technology and raising business performance, with better serving of clients.
India and China – analysis of pharma manufacturing service providers Our work assesses six Indian and Chinese companies. You discover activities and prospects of these firms: • Dr. Reddy’s Laboratories • Aurobindo Pharma • Divis Laboratories • Shandong Xinhua Pharmaceutical • Zhejiang Hisun Pharmaceutical • Zhejiang Huahai Pharmaceuticals.
That way you find sales data and underlying trends, exploring what the present and future hold.
Predictions for the worldwide pharma CMO market and submarkets Our report also forecasts revenues to 2025 for the world contract manufacturing industry and its main segments: APIs and FDFs.
That work predicts high sales growth from 2015 to 2025. Revenues can reach $80.5bn in 2019, with further expansion possible. We predict large companies and specialty healthcare firms will develop and prosper. She why, how and where, finding commercial potentials.
You also discover interviews with authorities in these three companies, hearing how firms think and view prospects for outsourced drug production: • Corden Pharma • Siegfried • PREMAS Biotech.
With our study you explore opportunities and sales predictions for outsourced production of medicines. You investigate established and rising companies, finding trends, outlooks and revenue potentials. See what is possible.
Ways Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025 helps your work In particular, our new investigation benefits your research, planning and decisions through the following analyses: • Revenues to 2025 for the world pharma contract manufacturing organisations (CMO) market – discover that industry’s prospects overall and by submarket, finding promising segments for investments, developments and revenue growth • Profiles of 30 leading companies there – assess services, strategies, sales results and outlooks, gaining revenue forecasts to 2025 for 26 of the firms, also with some profitability predictions • Interviews with three companies in the CMO industry – explore strategies, debates and opinions, helping you stay ahead in knowledge • Competition and opportunities – see what affects that industry, exploring what shapes its future, esp. prospects for sustaining and developing business • Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and succeed.
That report, by Visiongain’s in-house analysts in the UK, gives analysis with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.
Information there found nowhere else, helping you research, analyse and plan Our survey gives independent analysis. There you gain competitive intelligence found only in our report, exploring leading CMOs and their potentials.
By choosing our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses and decisions. Also see how you could save time and gain in recognition for technological and commercial insight.
Prospects for pharma manufacturing service providers – try our new analysis now Our new investigation gives you data, trends and business predictions for outsourced drug and API production. Avoid missing out – instead please get our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Leading Contract Manufacturing Organisations (CMOs) Overview 1.2 Benefits of This Report 1.3 How This Report Delivers Information 1.4 Main Questions This Report Answers 1.5 Who is This Report For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Related Reports 1.9 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2015 2.1 What Services Do Contract Manufacturers Offer? 2.1.1 Why Do Firms Outsource Manufacturing? 2.1.2 What Is Driving Demand for Contract Manufacturing Services? 2.2 The Pharmaceutical Contract Manufacturing Market, 2014 2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services? 2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2015-2025 2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2015-2025 2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2015-2025 2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2015-2025 2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?
3. Leading CMOs in North America 3.1 Catalent Pharma Solutions- One of the World’s Leading CMO 3.1.1 Catalent: Manufacturing Services and Capabilities 3.1.2 Divisional Segmentation – Breaking Down Catalent’s Service 3.1.3 Catalent Pharma’s Revenue Growth, 2010-2014 3.1.4 Sustained Growth in Oral Products: Catalent Pharma’s Divisional Performance, 2010-2014 3.1.5 Catalent Is Expanding its Oral Technologies Division 3.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity 3.1.7 Expansion of Packaging Services in Asia-Pacific and Europe: 2015 3.1.8 Adding New Early-Stage Development Services 3.1.9 Expansion in Japan – Growth Prospects for Catalent 3.1.10 New Business Contracts 2014-2015 3.1.11 Catalent New Products Launch 3.1.12 Catalent: Opportunities for Growth 2015-2025 3.1.13 Catalent: Mild Growth in Revenue, 2015-2025 3.2 Patheon – One of The Top 3 CMOs 3.2.1 Patheon – Global leader in Pharmaceutical Development Services 3.2.2 Contract Manufacturing Services at Patheon 3.2.3 Steady Revenue Growth 2010-2014 3.2.4 DPx Holdings: Developments 3.2.5 Adding New Formulations and Formulation Development Services 3.2.6 Reassessing Manufacturing Capacity 3.2.7 Expanding Services Through Acquisition, 2015 3.2.8 Patheon: SWOT Analysis 2015-2025 3.2.9 Patheon: Contract Manufacturing Revenue Forecast 2015-2025 3.3 Baxter BioPharma Solutions 3.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish 3.3.2 Historic Revenue Performance 2010-2014 3.3.3 Baxter BioPharma SWOT Analysis 2015-2025 3.3.4 Baxter BioPharma Revenue Forecast 2015-2025 3.4 AbbVie Contract Manufacturing 3.4.1 AbbVie Offers Full-Service Contract Manufacturing 3.4.2 Expanding and Adding New Services: 2013-2014 3.4.3 AbbVie Contract Manufacturing: Revenue 2011-2014 3.4.4 Biologics and HPAPIs Are an Opportunity for Growth 2015-2025 3.4.5 AbbVie Contract Manufacturing Revenue Forecast 2015-2025 3.5 Pfizer CentreSource 3.5.1 Pfizer CentreSource: Historic Revenue Performance, 2010-2014 3.5.2 Will Pfizer Divest CentreSource? 3.5.3 Outlook for CentreSource: Revenue Forecast 2015-2025
4. Leading European Contract Manufacturing Organisations 4.1 Lonza 4.1.1 Lonza Is a Leader in Biologics Manufacturing 4.1.2 Lonza Contract Manufacturing and Development: 2010-2014 4.1.3 Investing in Advanced Biological Drug Sectors 4.1.4 The Promise of Antibody-Drug Conjugates (ADCs) 4.1.5 The Regenerative Medicine Future in Japan 4.1.6 Lonza: SWOT Analysis 2015-2025 4.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2015-2025 4.2 Evonik Degussa 4.2.1 Investing in API and Drug Delivery Services 4.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2010-2014 4.2.3 Evonik Is a HPAPI Specialist 4.2.4 Evonik Continues to Grow Across All Segments 4.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market? 4.2.6 Evonik Degussa: Revenue Forecast 2015-2025 4.3 Royal DSM - The World’s Leading CMO 4.3.1 Amplified Revenue Growth in Pharma Manufacturing 2010-2014 4.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2010-2014 4.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing 4.3.4 DPx Holdings: A New Pharma Leader 4.3.5 Investing in Biopharma Manufacturing 4.3.6 Expanding API Manufacturing 4.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2025 4.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2015-2025 4.4 Boehringer Ingelheim Contract Manufacturing 4.4.1 Expanding Biopharmaceuticals Manufacturing Services in China 4.4.2 Production Through to Fill and Finished Biopharmaceuticals 4.4.3 A Track Record of Production for 29 Biopharma Products 4.4.4 Increasing Revenue from Contract Manufacturing, 2010-2014 4.4.5 Pulling Out of Small Molecule API Manufacturing 4.4.6 Expanding through New Services 4.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2015-2025 4.4.8 Boehringer Ingelheim: Revenue Forecast 2015-2025 4.5 Fareva 4.5.1 Fareva Has 35 Years’ Manufacturing Experience 4.5.2 Revenue Growth through Acquisitions: 2010-2014 4.5.3 Fareva SWOT Analysis: 2015 4.5.4 Fareva Revenue Forecast: 2015-2025 4.6 Aenova Group 4.6.1 Acquisition of Haupt Creates European CMO Giant 4.6.2 Aenova’s Ever Expanding Manufacturing Capacity 4.6.3 Aenova’s Revenue 2010-2014: Organic Growth and Acquisitions 4.6.4 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2015 4.6.5 Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2015-2025 4.7 Famar 4.7.1 Famar Is an Expert in Lyophilisation 4.7.2 Sustained Growth in Famar’s Revenue: 2010-2014 4.7.3 Expanding European Operations 4.7.4 Further Site Acquisitions Are an Opportunity for Growth 2015-2025 4.7.5 How Will Famar Perform 2015-2025? 4.8 Vetter Pharmaceutical 4.8.1 Vetter is an Injectable Manufacturing Specialist 4.8.2 Rapidly Growing Revenue in the US and Germany: 2010-2014 4.8.3 Services, Collaborations and Differentiating Factors 4.8.4 Expanding Services in US and Asia 4.8.5 Biologics Are an Opportunity for Growth for Vetter 2015-2025 4.8.6 Vetter Outlook: Revenue Forecast 2015-2025 4.9 Almac Group 4.9.1 Almac’s Manufacturing Services 4.9.2 Almac Outpaces the Market: 2011-2014 4.9.3 Almac Adding Capacity Globally 4.9.4 New Services Added 2012-2015 4.9.5 Almac Group: Contract Manufacturing Market Outlook 2015-2025 4.9.6 How Will Almac Group Perform 2015-2025? 4.10 Delpharm 4.10.1 Finished Dosage Form Manufacturing for Developed Markets 4.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2010-2014 4.10.3 Delpharm: Outlook and Prospects for Growth 2015-2025 4.10.4 Generics Will Drive Revenue Growth for Delpharm 2015-2025 4.11 Siegfried 4.11.1 Siegfried’s Acquisitions, 2010-2014 4.11.2 Expanding Siegfried’s Manufacturing Footprint Globally 4.11.3 Expanding High Potency API Capabilities 4.11.4 Siegfried: Financial Performance 2010-2014 4.11.5 Siegfried’s Characteristics within the Contract Manufacturing Market: SWOT Analysis 2015 4.11.6 Continued Revenue Growth for Siegfried 2015-2025 4.12 Corden Pharmaceutical 4.12.1 CordenPharma Service Division 4.12.2 CordenPharma Emerging in the API Market 4.12.3 Investments in Highly Potent Capabilities 4.12.4 CordenPharma: SWOT Analysis 2015-2025 4.13 Recipharm 4.13.1 Contract Development and Manufacturing Services 4.13.2 Recipharm: Financial Performance 2010-2014 4.13.3 Recipharm Invests in Facility Expansion 4.13.4 Recipharm Growing in Development & Technology Market through Acquisitions 4.13.5 Recipharm: Opportunities for Growth 2015-2025 4.13.6 Outlook for Recipharm: Revenue Forecast 2015-2025 4.14 Aesica Pharmaceuticals 4.14.1 Aesica Manufactures APIs and Finished Dosage Forms 4.14.2 Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2010-2014 4.14.3 Partnering with Academia for Innovative Solutions 4.14.4 Growth through Acquisitions and Internal Expansion 4.14.5 Aesica: Opportunities for Expansion 2015-2025 4.14.6 Forecast Aesica Financial Performance, 2015-2025
5. Leading Japanese Pharma Contract Manufacturing Organisations 5.1 Nipro Corporation: Japan’s Leading CMO 5.1.1 Nipro Pharmaceutical Contract Manufacturing Capabilities 5.1.2 Nipro: Decline in Revenue But Increasing Operating Profits 2010-2014 5.1.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2015 5.1.4 Nipro Revenue and Profitability Forecast 2015-2025 5.2 Daito Pharmaceutical 5.2.1 Daito Has a Portfolio of More than 30 APIs 5.2.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2010-2014 5.2.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2015-2025 5.2.4 Sustained Growth in Revenue and Operating Profit for Daito, 2015-2025
6. Leading Developed-Market API Specialists 6.1 Teva API 6.1.1 API Manufacturing Services 6.1.2 Teva API: Financial Performance 2010-2014 6.1.3 Building a Footprint in Mexico, India and China 6.1.4 Teva API: SWOT Analysis 2015 6.1.5 Outlook for Teva API: Revenue Forecast 2015-2025 6.2 Esteve Química 6.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets 6.2.2 Expanding in The US, 2015 6.2.3 Esteve Química: SWOT Analysis 2015-2025 6.3 Euticals 6.3.1 Euticals Manufactures More than 200 APIs 6.3.2 Acquisitions Drive Growth 2010-2014 6.3.3 Adding Capacity for Finished Dosage Forms 6.3.4 Asian Expansion Is an Opportunity for Growth 2015-2025 6.3.5 Euticals: Revenue Forecast 2015-2025
7. Leading Chinese Pharmaceutical Contract Manufacturers 7.1 Zhejiang Hisun Pharmaceutical 7.1.1 API Manufacturing for Markets Worldwide 7.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2010-2014 7.1.3 Moving Into International Drug Marketing 7.1.4 Zhejiang Hisun: Opportunities for Growth 2015-2025 7.1.5 Zhejiang Hisun: Strong API Revenue Growth 2015-2025 7.2 Zhejiang Huahai Pharmaceuticals 7.2.1 Zhejiang Huahai Is a Market Leader Within The Antihypertensive API Market 7.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2010-2014 7.2.3 Expanding in the US Generic Drugs Market 7.2.4 Zhejiang Huahai: SWOT Analysis, 2015 7.2.5 Zhejiang Huahai: Revenue Forecast, 2015-2025 7.3 Shandong Xinhua Pharmaceutical 7.3.1 Experience in APIs and Finished Dosage Forms 7.3.2 Shandong Xinhua: Strong Revenue Growth 2010-2014 7.3.3 Growing through Joint Ventures 7.3.4 Looking to Expand in the US and EU 2015-2025 7.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2015-2025
8. Leading Indian Pharmaceutical Contract Manufacturers 8.1 Aurobindo Pharma 8.1.1 API Manufacturing Services 8.1.2 Aurobindo Pharma: Steady Revenue Growth 2010-2014 8.1.3 Aurobindo Expanding Outside of Antibacterials 8.1.4 Aurobindo: Opportunities for Expansion 2015-2025 8.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2015-2025? 8.2 Divis Laboratories 8.2.1 Divis Laboratories and the Contract Manufacturing Industry 8.2.2 Divis Laboratories: A Rapidly Growing CMO, 2010-2014 8.2.3 Divis Laboratories: API Manufacturing Outlook 2015-2025 8.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2015-2025 8.3 Dr. Reddy’s Laboratories 8.3.1 API and FDF Manufacturing Services 8.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2010-2014 8.3.3 Advancing in Complex Drug Manufacturing 8.3.4 Expanding in the European Manufacturing Market 8.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2015-2025
9. Research Interviews from Our Industry Survey 9.1 Dr Michael Quirmbach, Vice President, Global Sales & Marketing, CPI, Corden Pharma 9.2 Mrs Marianne Spaene, Executive Vice President, Global Head Business Development, Sales and Marketing, Siegfried 9.3 Dr Prabuddha Kundu, Cofounder & Executive Director, PREMAS Biotech
10. Conclusions of the Study 10.1 What Has Driven Growth for CMO Market Leaders in Recent Years? 10.2 Strategies for Growth: Prospects For Leading CMOs, 2015-2025 10.3 High Demand for Biopharmaceutical Manufacturing Services 10.4 Investing in Novel Technologies 10.5 Outlook for API Manufacturers
Abbott Laboratories Abic AbbVie Actavis Adamas Pharmaceuticals Aegerion Aenova Group Aesica Pharmaceuticals Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Agência Nacional de Vigilância Sanitária (ANVISA) Agennix Aguettant AlgoNomics Alliance Medical Products Almac Group Alpharma Amgen AMYRA Biotech Andeno Apexigen Aptuit Archimica Arecor ArGEN-X Astellas AstraZeneca Athera Biotechnologies Aurobindo Pharma Avalanche Biotechnologies Banner Life Sciences BaroFold Barr-Pliva BASF Baxter BioPharma Solutions Bayer BC Partners Becton and Dickinson (BD) Beijing Double-Crane Pharmaceutical Bentley Biocraft Biogal Biomedical Advanced Research and Development Authority (BARDA) Bionomics Biotest BioWa Boehringer Ingelheim Bridgepoint Capital Bristol-Myers Squibb Britest Canyon Carbogen Amcis Cardinal Health Catalent Celladon Celldex Therapeutics Celsion CEVEC Pharmaceuticals Chemtrix BV China National Pharmaceutical Group (SInopharm) Chirotech Circadian Technologies Cleveland BioLabs Cobra Biomanufacturing Companies House CordenPharma Corvette Pharmaceutical Services Daiichi Sankyo Daito DecImmune Therapeutics Delmas Perfusion Delpharm Divis Laboratories DPx Holdings Dr. Reddy’s Laboratories Dragenopharm Apotheker Püschl and Swiss Caps Eclipse Therapeutics Eindhoven University of Technology Eisai Eli Lilly EmulTech Esteve Química Euro Vital Pharma European Medicines Agency (EMA) Euticals Evonik Degussa Excella Exelixis Famar Fareva Farmaprojects Frazier Healthcare Fuyang Xinghai Investment Genentech Générique Même Médicament (GEMME) Genzyme GSK Corixa Haupt Pharma Health Canada Hejiang Jiang Yuan Tang Biotechnology Human Genome Sciences ICI Immune Pharmaceuticals Immunomedics Index Ventures Indoco Remedies Intellect Neurosciences International Chemical Investors Group Ivax API Japanese Ministry of Health Labor and Welfare (MHWL) Japanese Pharmaceutical and Medical Devices Agency (PMDA) JK Pharmaceutical JLL Partners Johnson & Johnson (J&J) Kadmon Laboratoires Besins Lanxess Corporation LBO Italia Investimenti s.r.l Lonza Marinopoulos Group. MedImmune Merck KGaA Merck Serono Mesoblast Molecular Partners Moody’s Corporation Mylan NIH CRM Nipro Corporation Novartis Novasep Novozymes NPS OctoPlus OncoMed Pharmaceuticals Opthea Osiris Therapeutics Otsuka Pharmaceutical Pantec Patheon Perrigo PFC Pfizer Pharmacia Pharmacyclis Pharmintraco Piramal Plantex Poli Industria Chimica Progenics Pharmaceuticals Prosintex R5 Pharmaceuticals RAG AG Ranbaxy Labs Recipharm Regeneus Relthy Laboratórios Relypsa Respirics Rexim Roche Royal DSM Sandoz Sanofi Sanquin Blood Supply foundation Sanwa Kagaku Kenkyusho Schering ScinoPharm Seattle Genetics Sentry BioPharma Services Servier Shandong Tianda Biological Pharmaceutica Shandong Xinhua Pharmaceutical Shanghai Pharmaceutical ShangPharma Shire Sicor Siegfried Sigmar Italia Silverfleet Capital Sinochem SkyePharma Solvay Sun Pharma Supernus Pharmaceuticals SurModics Swedbank Swedish Orphan Biovitrium AB (Sobi) Synkem Syntex Synthon Takeda Temmler Group Tessenderlo Group Teva Pharmaceutical Industries Theramax Tianjin Tianyo Pharmaceuticals Tianma Tianji Tunitas Therapeutics UCB UK Health and Safety Executive UK Medicines and Healthcare Products Regulatory Agency (MHRA) UMN Pharma UniQure University College London (UCL) University of Bradford University of Durham University of Leeds US Food and Drug Administration (FDA) Vetter Pharma Vidara ViroPharma Vivante GMP Solutions VTU Technology West Pharma Wockhardt XOMA Yiwu Huayi Investment Zhangjiang Biotech & Pharmaceutical Base Company Zhejiang Hisun Pharmaceutical Zhejiang Huahai Pharmaceuticals
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
